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Growth factors are polypeptides that are involved in the
regulation of cell growth and differentiation, such as, during the
embryonal development, in wound healing, in hematopoiesis, in
the immune response, as well as in several adverse reactions
including malignancies. Several families of structurally-related
growth factors are known; new members of these families
continue to be discovered and occasionally new families are
found. One of the best characterized growth factor family is the
platelet-derived growth factor (PDGF) family. PDGF was orig-
inally found to be present in the a-granules of platelets and to
have growth promoting activity for fibroblasts and smooth
muscle cells; subsequent studies have shown that PDGF is
synthesized by a large number of different normal as well as
transformed cell types, and that it acts not only on connective
tissue cells but also on other types of cells [reviewed in 1, 21.
The present review summarizes some recent developments in
the elucidation of the structural and functional properties of
PDGF and PDGF receptors, the mechanism for PDGF signal-
ling at the cellular level and the possible in vivo effects of
PDGF.
Different isoforms of PDGF
PDGF is a family of closely related 30 kDa proteins made up
of disulfide-bonded dimers of A- and B-polypeptide chains
(PDGF-AA, PDGF-AB or PDGF-BB) [3-5]. Both PDGF chains
are synthesized as precursor molecules that undergo proteolytic
processing after biosynthesis and dimerization. The different
isoforms of PDGF differ in their functional properties (see
further below) as well as in their secretory behaviors. Both the
A-chain and B-chain precursors contain hydrophobic leader
sequences. However, only PDGF-AA and -AB are efficiently
secreted from the producer cells; a major part of PDGF-BB
undergoes further proteolysis to a 24 kDa form and remains cell
associated [6—8]. The structural determinant in the B-chain
responsible for the retention is a sequence of basic amino acids
in the C-terminus [9]. Whereas this motif is not found in the
short, most abundant form of the A-chain, a similar sequence is
present in a longer splice variant of the A-chain, which was also
found to be retained by the producer cell [9]. These results
therefore suggest that the compartmentalization of PDGF-AA is
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regulated by differential splicing. The functional implication of
the cell retention of PDGF is not known, but may determine
whether the effect of the growth factor will be preferentially
autocrine or paracrine.
Two distinct receptor types
Two different PDGF receptor types have been identified; the
a-receptor binds all PDGF isoforms with high affinity, whereas
the /3-receptor only binds PDGF-BB with high affinity and
PDGF-AB with lower affinity [10, 11]. The two receptor types
are structurally related; their extracellular parts each contain
five immunoglobulin-like domains, and the intracellular parts
contain protein tyrosine kinase domains with characteristic
insert sequences of about 100 amino acids without homology to
kinase domains [12—14]. These structural characteristics of the
PDGF receptors are also shared by the CSF-l receptor and the
c-kit product [15].
Signalling through homodimeric or heterodimeric receptor
complexes
Binding of PDGF to the extracellular part of the receptor
induces dimerization of the receptors [16—18]. The dimerization
probably occurs through binding of each subunit in the PDGF
molecule to one receptor molecule, whereby the ligand forms a
bridge between two receptors; the A-chain of PDGF interacts
with a-receptors, whereas the B-chain interacts both with a-
and /3-receptors. This would imply that, for example,
PDGF-AB could induce heterodimeric complexes by simulta-
neously binding with its A-chain to an a-receptor and its
B-chain to a /3-receptor. PDGF receptor heterodimers have
been demonstrated on cells having both a- and /3-receptors [19]
(Eriksson et al, Growth Factors, in press). Furthermore, using
PDGF-induced actin reorganization as an assay, it was demon-
strated that PDGF-AB acted as a PDGF /3-receptor agonist in
the presence of a-receptors, but as a PDGF /3-receptor antag-
onist in the absence of a-receptors [201. These observations
support the notion that dimerization correlates with activation
of the receptor, whereas monovalent binding of the ligand to a
single receptor molecule is not sufficient for activation.
Whether PDGF receptor heterodimers have distinct functional
properties not associated with receptor homodimers, is an
interesting possibility which remains to be elucidated.
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The mechanism whereby receptor dimerization leads to acti-
vation of the kinase is not known. It is possible that the two
receptor molecules in the dimer phosphorylate each other in
trans, and that this "autophosphorylation" is involved in the
activation mechanism [211. In support of this possibility, over-
expression of a truncated receptor lacking almost the entire
cytoplasmic domain was found to inhibit the activation of
wild-type PDGF receptors, presumably via formation of inac-
tive heterodimeric complexes with wild type receptors [221.
The two PDGF receptor types mediate different signals.
Using porcine aortic endothelial cells transfected with either a-
or /3-receptors, both receptor types were found to mediate
mitogenicity, but only the /3-receptor was capable of mediating
chemotaxis and circular actin reorganization (Eriksson et al,
EMBOJ, in press). Analysis of the substrate specificities of the
a- and 13-receptor kinases revealed similarities as well as
differences; it is likely that components phosphorylated by the
/3-receptor, but not by the a-receptor, are involved in the
mediation of chemotaxis and actin reorganization.
There is compelling evidence that the phosphorylation of
tyrosine residues of specific substrates is involved in signal
transduction via the PDGF receptors. Thus, a receptor in which
the kinase activity had been extinguished by a point mutation
was unable to mediate mitogenicity, chemotaxis, or actin reor-
ganization [23, 241. Among the identified substrates for the
PDGF receptors are phospholipase C-)' [25, 26], GTPase acti-
vating protein [27], the regulatory subunit of phosphatidylino-
sitol-3 '-kinase [28—31], and members of the pp6Osrc family of
protein tyrosine kinases [32]. All these proteins have a con-
served structural motif, denoted "src homology region 2" or
SH2, and it has been found that this domain mediates a physical
interaction with activated growth factor receptors [33]. The
exact effects of tyrosine phosphorylation on the intrinsic activ-
ities of the different substrates are still incompletely known, and
their possible roles in the mitogenic pathway of PDGF remain
to be determined. The serine/threonine kinase Raf- I is activated
in PDGF-stimulated cells by an indirect mechanism involving
phosphorylation of the enzyme on serine residues [34, 35].
Raf-l appears to be phosphorylated on tyrosine residues [35],
but it is unclear whether this is related to the activation of the
enzyme. Raf-l may have a crucial role in the transduction of the
mitogenic signal of PDGF, since microinjection of Raf-i is
sufficient to induce DNA synthesis [36], and since expression of
raf-l antisense RNA inhibits cell growth [37].
In vivo function of PDGF
The in vivo function of PDGF has not yet been fully eluci-
dated. The observations that PDGF is expressed in mouse [38]
and Xenopus [39] embryos, as well as in the placenta [40],
suggest that PDGF has a role in the regulation of cell growth
and differentiation during the development. This notion is
further strengthened by the finding that the a-receptor is
expressed in the early mouse embryo [41]. A function for PDGF
has, furthermore, been demonstrated in glial cell development;
PDGF-AA secreted by type-i astrocytes of the rat optic nerve
controls the differentiation of O-2A progenitor cells, which have
PDGF a-receptors, into oligodendrocytes and type-2 astrocytes
[42-453. It is possible that PDGF has additional roles during the
development of the central nervous system, since PDGF is
present in different parts of the brain of embryonic and adult
mice [46, 471, and since neuronal cells have functional PDGF
13-receptors [48]. In the adult, PDGF has been suggested to have
a function in the physiological hypertrophy of the uterus during
pregnancy, since the expression of PDGF A-chain was found to
increase in human uterus during pregnancy [49]. Furthermore,
since PDGF is released by platelets and by cells involved in the
inflammatory reaction, and since it stimulates proliferation as
well as chemotaxis of connective tissue cells, it is conceivable
that PDGF has a role in the stimulation of tissue repair
processes. Experimental support for such a role of PDGF has
been obtained using different in vivo models for wound healing.
Thus, PDGF administered in collagen gels in Gortex tubes
inserted into the skin of rats, was found to promote the
formation of granulation tissue [50], and local application of
PDGF-BB increased the strength of healing wounds [51].
PDGF in adverse reactions
In addition to its possible beneficial roles in normal develop-
ment and in tissue repair processes, PDGF may also be in-
volved in adverse reactions, such as malignancies and other
conditions involving an excess of cell proliferation. The B-chain
of PDGF is virtually identical to p28s1s, the transforming protein
of simian sarcoma virus (SSV) [52, 53], and several lines of
evidence support the conclusion that a PDGF-like mitogen
exerts the transforming effect of SSV through an autocrine
mechanism [reviewed in 54]. These observations provided a
firm link between growth factors and oncogenic transformation,
and stimulated investigations on the expression PDGF and
PDGF receptors in human tumors. The results of such studies
show that coexpression of PDGF and PDGF receptors is
common in certain tumor types, as well as in cell lines derived
from such tumors. These data support the notion that PDGF
may be involved in autocrine and paracrine stimulation of
tumor growth [reviewed in 1, 2, 54].
PDGF may also have a causative role in non-malignant
conditions involving an excess of cell proliferation. Thus, the
stimulatory effect of PDGF on smooth muscle cells may, at sites
of injuries to the endothelial layer of the vessel lumen, cause an
unscheduled proliferation and migration of smooth muscle cells
into the intima of the vessel wall, and thereby promote athero-
sclerosis [reviewed in 55]. In chronic inflammatory conditions,
the stimulatory effect of PDGF on connective tissue cells may
lead to tissue fibrosis [56]. Moreover, PDGF produced by
mesangial cells or inflammatory cells may contribute to the
development of glomerulonephritis through autocrine or para-
crine mechanisms (Johnsson et at, this issue).
Of importance for the understanding of the in vivo effects of
PDGF is the observation that the expression of PDGF 13-recep-
tors on putative target cells in vivo is regulated by factors in the
cellular environment. Thus, the PDGF /3-receptor is expressed
only at low levels on fibroblasts of the skin, or on smooth
muscle cell of the uterus myometrium, despite the fact that the
corresponding cell types have 13-receptors when cultured in
vitro [57]. PDGF 13-receptors were found to be induced, how-
ever, in conjunction with inflammatory reactions in vivo [58].
Analogously, the stimulatory effect of PDGF on rat liver
fat-storing cells [59] becomes enhanced after treatment of the
cells with conditioned medium from Kupifer cells; the mecha-
nism for this effect involves an induction of PDGF receptors
[60]. Furthermore, 13-receptors are induced on Schwann cells
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after increase of the cAMP concentration [611, and a-receptors
are down-regulated on fibroblasts after treatment with TGF-/3
[621. Taken together, these data indicate that the responsive-
ness of cells for PDGF in vivo may depend not only on the
availability of the ligand, but also on the regulated expression of
PDGF receptors on the target cells.
Future perspectives
Work performed in recent years has provided information on
the structure of PDGF and PDGF receptors, and an initial
insight into the mechanism of signal transduction via PDGF
receptors. Some information has also emerged on the role of
PDGF in vivo, in normal tissues as well as in disease. Important
goals for future studies will be to characterize the effects of
PDGF administered in vivo and to explore the possibility that
PDGF can be used clinically, for example, to stimulate wound
healing. Equally important will be to develop specific antago-
nists for PDGF action, and to investigate their possible clinical
use to inhibit unscheduled autocrine and paracrine PDGF
stimulation, such as that found in malignancies and in chronic
inflammatory reactions.
Reprint requests to Carl-Henrik He/din, MD., Ludwig institute for
Cancer Research, Uppsala Branch, Biomedical Center, Box 595, S-751
24 Uppsa!a, Sweden.
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